JP2012533560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012533560A5 JP2012533560A5 JP2012520795A JP2012520795A JP2012533560A5 JP 2012533560 A5 JP2012533560 A5 JP 2012533560A5 JP 2012520795 A JP2012520795 A JP 2012520795A JP 2012520795 A JP2012520795 A JP 2012520795A JP 2012533560 A5 JP2012533560 A5 JP 2012533560A5
- Authority
- JP
- Japan
- Prior art keywords
- molecule
- sequence
- consecutive
- amino acids
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940024606 amino acid Drugs 0.000 claims description 36
- 235000001014 amino acid Nutrition 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 235000009697 arginine Nutrition 0.000 claims description 12
- 150000001484 arginines Chemical class 0.000 claims description 12
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 11
- 230000002378 acidificating effect Effects 0.000 claims description 11
- 229940009098 aspartate Drugs 0.000 claims description 11
- 229930195712 glutamate Natural products 0.000 claims description 11
- 150000002306 glutamic acid derivatives Chemical class 0.000 claims description 8
- 150000008574 D-amino acids Chemical class 0.000 claims description 4
- 102000005741 Metalloproteases Human genes 0.000 claims description 4
- 108010006035 Metalloproteases Proteins 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 4
- 239000004365 Protease Substances 0.000 claims description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 210000001723 extracellular space Anatomy 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims 1
- 229960002684 aminocaproic acid Drugs 0.000 claims 1
- 239000007850 fluorescent dye Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 12
- 206010028980 Neoplasm Diseases 0.000 description 9
- -1 6-aminohexanoyl Chemical group 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 8
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 238000003384 imaging method Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 239000002534 radiation-sensitizing agent Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 239000002616 MRI contrast agent Substances 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 230000005298 paramagnetic effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000035346 Margins of Excision Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22587209P | 2009-07-15 | 2009-07-15 | |
| US61/225,872 | 2009-07-15 | ||
| PCT/US2010/042184 WO2011008992A2 (en) | 2009-07-15 | 2010-07-15 | Peptides whose uptake in cells is controllable |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012533560A JP2012533560A (ja) | 2012-12-27 |
| JP2012533560A5 true JP2012533560A5 (enExample) | 2013-08-29 |
Family
ID=43450218
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520795A Pending JP2012533560A (ja) | 2009-07-15 | 2010-07-15 | 細胞における取り込みが制御可能なペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US9682151B2 (enExample) |
| EP (2) | EP2453926A4 (enExample) |
| JP (1) | JP2012533560A (enExample) |
| CN (1) | CN102858794A (enExample) |
| AU (1) | AU2010273321A1 (enExample) |
| CA (1) | CA2770980A1 (enExample) |
| WO (2) | WO2011008996A2 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7985401B2 (en) * | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
| US8153435B1 (en) | 2005-03-30 | 2012-04-10 | Tracer Detection Technology Corp. | Methods and articles for identifying objects using encapsulated perfluorocarbon tracers |
| EP2403964B1 (en) | 2009-03-02 | 2021-09-08 | Massachusetts Institute of Technology | Methods and products for in vivo enzyme profiling |
| EP2453926A4 (en) * | 2009-07-15 | 2015-08-12 | Univ California | PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING |
| ES2881535T3 (es) | 2011-03-15 | 2021-11-29 | Massachusetts Inst Technology | Detección multiplexada con indicadores codificados con isótopos |
| DK2736533T3 (en) | 2011-07-29 | 2018-08-06 | Avelas Biosciences Inc | SELECTIVE SUBMISSION MOLECULES AND METHODS OF USE |
| US8871189B2 (en) | 2011-11-30 | 2014-10-28 | Mallinckrodt Llc | MMP-targeted therapeutic and/or diagnostic nanocarriers |
| US9355654B1 (en) | 2012-12-21 | 2016-05-31 | Western Digital Technologies, Inc. | Spin torque oscillator for microwave assisted magnetic recording with increased damping |
| US10029017B2 (en) | 2013-01-29 | 2018-07-24 | The Regents Of The University Of California | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug |
| CN105102484B (zh) | 2013-01-30 | 2020-03-10 | 艾维拉斯生物科学公司 | 选择性递送分子及使用方法 |
| PT2978859T (pt) | 2013-03-27 | 2018-10-04 | Hoffmann La Roche | Marcadores genéticos para previsão da capacidade de resposta à terapêutica |
| HK1222122A1 (zh) * | 2013-04-22 | 2017-06-23 | Avelas Biosciences, Inc. | 选择性药物递送组合物及使用方法 |
| WO2014183119A1 (en) * | 2013-05-10 | 2014-11-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Molecular imaging probes for lung cancer inoperative guidance |
| WO2014197840A1 (en) | 2013-06-07 | 2014-12-11 | Massachusetts Institute Of Technology | Affinity-based detection of ligand-encoded synthetic biomarkers |
| WO2015028614A1 (en) * | 2013-08-30 | 2015-03-05 | Novo Nordisk A/S | Generation of endocrine progenitor cells from human pluripotent stem cells using small molecules |
| US10029014B2 (en) | 2013-09-10 | 2018-07-24 | The Research Foundation For The State University Of New York | Synthesis of novel asymmetric bow-tie PAMAM dendrimer-based conjugates for tumor-targeting drug delivery |
| RU2703192C2 (ru) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
| CN104792979B (zh) * | 2014-09-05 | 2017-02-01 | 昆明医科大学第一附属医院 | 一种检测人基质金属蛋白酶‑12活性的荧光多肽底物 |
| GB201417067D0 (en) | 2014-09-26 | 2014-11-12 | South African Nuclear Energy | Radiopharmaceutical conjugate |
| US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
| US10596259B2 (en) | 2015-05-20 | 2020-03-24 | The Regents Of The University Of California | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof |
| EP3440013A4 (en) | 2016-04-08 | 2021-03-17 | Massachusetts Institute of Technology | METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES |
| CA3022928A1 (en) | 2016-05-05 | 2017-11-09 | Massachusetts Institute Of Technology | Methods and uses for remotely triggered protease activity measurements |
| WO2018134265A1 (en) | 2017-01-17 | 2018-07-26 | Forrest Michael David | Therapeutic inhibitors of the reverse mode of atp synthase |
| AU2018248327B2 (en) | 2017-04-07 | 2024-10-10 | Massachusetts Institute Of Technology | Methods to spatially profile protease activity in tissue and sections |
| IL271845B2 (en) | 2017-07-13 | 2024-06-01 | Michael David Forrest | Therapeutic modulators of the reverse mode of atp synthase |
| US11054428B2 (en) | 2018-03-05 | 2021-07-06 | Massachusetts Institute Of Technology | Inhalable nanosensors with volatile reporters and uses thereof |
| WO2019204363A2 (en) * | 2018-04-16 | 2019-10-24 | Avelas Biosciences, Inc. | Selective delivery of therapeutic and imaging agents |
| WO2020068920A2 (en) | 2018-09-25 | 2020-04-02 | Massachusetts Institute Of Technology | Lung protease nanosensors and uses thereof |
| EP3628309A1 (en) * | 2018-09-28 | 2020-04-01 | Universität Heidelberg | Method of making oral dosage forms |
| EP3886912A4 (en) * | 2018-11-29 | 2023-01-04 | Starpharma Pty Limited | DENDRIMER FOR THERAPY AND IMAGING |
| WO2020150560A1 (en) | 2019-01-17 | 2020-07-23 | Massachusetts Institute Of Technology | Sensors for detecting and imaging of cancer metastasis |
| IT201900002321A1 (it) * | 2019-02-18 | 2020-08-18 | Univ Degli Studi Padova | Peptidi con attivita' antitumorale |
| AU2021284918A1 (en) * | 2020-06-03 | 2023-01-05 | Starpharma Pty Ltd | Therapeutic conjugates |
| CN116438456A (zh) | 2020-09-11 | 2023-07-14 | 格里姆普斯生物股份有限公司 | 用于疾病检测/诊断、分期、监测和治疗的离体蛋白酶活性检测 |
| WO2022157548A1 (en) | 2021-01-24 | 2022-07-28 | Forrest Michael David | Inhibitors of atp synthase - cosmetic and therapeutic uses |
| CN115385988B (zh) * | 2022-05-25 | 2023-04-11 | 广州医科大学 | 一种mmp酶响应型肿瘤靶向多肽载体及其应用 |
| CN116063389B (zh) * | 2022-08-23 | 2023-07-07 | 广州医科大学 | 递送核酸药物的多肽载体、治疗肿瘤的核酸药物及其制备方法 |
| AU2023333045A1 (en) * | 2022-08-31 | 2025-04-10 | Transfection Holdings Limited | Chemical conjugates, compositions, and methods of preparation and use thereof |
| KR20250118248A (ko) * | 2022-11-14 | 2025-08-05 | 악티스 온콜로지, 인크. | 신장 내 미니단백질의 감소된 체류 |
| AU2024351474A1 (en) | 2023-09-29 | 2026-05-07 | Aktis Oncology, Inc. | Miniproteins, conjugates & uses thereof |
| CN118955414B (zh) * | 2024-10-17 | 2025-03-18 | 南昌大学 | 两亲性Eu配合物及其制备方法与在检测四环素中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4507389A (en) | 1982-12-16 | 1985-03-26 | Monsanto Company | Determination of collagenase by reacting with peptide substrates |
| US4466919A (en) | 1982-12-16 | 1984-08-21 | Monsanto Company | Peptide substrates for mammalian collagenase |
| GB8927722D0 (en) | 1989-12-07 | 1990-02-07 | British Bio Technology | Proteins and nucleic acids |
| US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
| EP0800545B2 (en) | 1995-11-01 | 2011-03-02 | Bracco Research S.A. | Targeted magnetically labeled molecular marker systems for the nmr imaging |
| US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
| GB9708265D0 (en) * | 1997-04-24 | 1997-06-18 | Nycomed Imaging As | Contrast agents |
| CA2291074C (en) | 1997-05-21 | 2008-04-01 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for enhancing transport across biological membranes |
| US6083486A (en) | 1998-05-14 | 2000-07-04 | The General Hospital Corporation | Intramolecularly-quenched near infrared fluorescent probes |
| US6592847B1 (en) | 1998-05-14 | 2003-07-15 | The General Hospital Corporation | Intramolecularly-quenched near infrared flourescent probes |
| CA2328457A1 (en) | 1998-06-20 | 1999-12-29 | Washington University | Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US20020009786A1 (en) | 2000-04-18 | 2002-01-24 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| AU2002220082A1 (en) | 2000-10-19 | 2002-04-29 | The General Hospital Corporation | Imaging of enzymatic activity |
| US7179784B2 (en) | 2001-07-10 | 2007-02-20 | Massachusetts Institute Of Technology | Surfactant peptide nanostructures, and uses thereof |
| AU2003291325A1 (en) | 2002-11-04 | 2004-06-07 | Fred Hutchinson Cancer Research Center | Method for the linear amplification of complementary dna |
| US7371364B2 (en) | 2003-08-15 | 2008-05-13 | Board Of Regents, The University Of Texas System | Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy |
| US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
| US7985401B2 (en) * | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| US7431915B2 (en) * | 2003-10-31 | 2008-10-07 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| CA2583389A1 (en) * | 2004-10-07 | 2006-04-20 | Emory University | Multifunctional nanoparticles conjugates and their use |
| TW201004647A (en) | 2008-05-20 | 2010-02-01 | Sigma Tau Ind Farmaceuti | Novel dual targeting antitumoural conjugates |
| KR101095841B1 (ko) | 2009-02-19 | 2011-12-21 | 주식회사 나이벡 | 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
| EP2453926A4 (en) * | 2009-07-15 | 2015-08-12 | Univ California | PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING |
| JP5646923B2 (ja) | 2010-09-03 | 2014-12-24 | 矢崎総業株式会社 | 車両用表示装置及び車両用表示システム |
| DK2736533T3 (en) | 2011-07-29 | 2018-08-06 | Avelas Biosciences Inc | SELECTIVE SUBMISSION MOLECULES AND METHODS OF USE |
| US10029017B2 (en) | 2013-01-29 | 2018-07-24 | The Regents Of The University Of California | Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug |
-
2010
- 2010-07-15 EP EP10800571.1A patent/EP2453926A4/en not_active Withdrawn
- 2010-07-15 WO PCT/US2010/042188 patent/WO2011008996A2/en not_active Ceased
- 2010-07-15 WO PCT/US2010/042184 patent/WO2011008992A2/en not_active Ceased
- 2010-07-15 CN CN2010800419072A patent/CN102858794A/zh active Pending
- 2010-07-15 EP EP10800568.7A patent/EP2454271A4/en not_active Withdrawn
- 2010-07-15 US US13/384,591 patent/US9682151B2/en active Active
- 2010-07-15 AU AU2010273321A patent/AU2010273321A1/en not_active Abandoned
- 2010-07-15 US US13/384,581 patent/US9808532B2/en active Active
- 2010-07-15 CA CA2770980A patent/CA2770980A1/en not_active Abandoned
- 2010-07-15 JP JP2012520795A patent/JP2012533560A/ja active Pending
-
2017
- 2017-02-08 US US15/427,427 patent/US20170305968A1/en not_active Abandoned
-
2019
- 2019-06-28 US US16/457,763 patent/US11246940B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240101601A1 (en) | Bi-terminal pegylated integrin-binding peptides and methods of use thereof | |
| JP5819824B2 (ja) | ε−ポリリシン接合体およびその使用 | |
| JP4936312B2 (ja) | 新規な両親媒性物質、それを用いた薬剤搬送システム及び分子イメージングシステム | |
| JP2014521661A5 (enExample) | ||
| US20100267928A1 (en) | Activatable diagnostic and therapeutic compound | |
| JP2020079288A (ja) | 悪性腫瘍標的ペプチド | |
| EP1210121A2 (en) | Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties | |
| CN103687624A (zh) | 靶向的聚合缀合物和其用途 | |
| ES2745745T3 (es) | Polipéptidos entrecruzados autoensamblados en forma de estrella y su uso como transportadores en aplicaciones biomédicas | |
| EP2449379A1 (en) | Fluorescent silica-based nanoparticles | |
| JP6602034B2 (ja) | 標的化分子およびその使用 | |
| US20120244070A1 (en) | Fibronectin targeting contrast agent | |
| US20190160172A1 (en) | Bone fracture repair by targeting of agents that promote bone healing | |
| Chen et al. | Pathological environment directed in situ peptidic supramolecular assemblies for nanomedicines | |
| Ornelas-Megiatto et al. | Interlocked systems in nanomedicine | |
| An et al. | Peptide-based nanostructures for cancer diagnosis and therapy | |
| WO2019009434A1 (ja) | 薬物送達用高分子ミセル | |
| CN102271713A (zh) | 神经降压肽衍生的分枝肽及其用途 | |
| JP2008522666A5 (enExample) | ||
| KR20070029200A (ko) | 펩티드계 화합물 | |
| Alshehri et al. | In Vitro Evaluation and Biodistribution Studies of HPMA Copolymers Targeting the Gastrin Releasing Peptide Receptor in Prostate Cancer: Alshehri, Fan, Zhang and Garrison | |
| CN114174318A (zh) | 生物降解性优异的肾靶向型药物递送用载体 | |
| De Marco | Multi-targeting approach of alphavbeta3 integrin ligands and their applications in diagnostic field and cancer therapy | |
| JP6924191B2 (ja) | 新規な高分子誘導体、及びそれらを用いた新規な高分子誘導体イメージングプローブ | |
| CN118556068A (zh) | Cd44结合肽试剂和方法 |